Current and Future Treatments in Alzheimer Disease: An Update
By K. Yiannopoulou, Sokratis G. Papageorgiou. Journal of Central Nervous System Disease, 2020
760 citations recorded by the source corpus.
Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research. Nowadays, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance: 3 cholinesterase inhibitors and memantine. To block the progression of the disease, therapeutic agents are supposed to interfere with the pathogenic steps responsible for the clinical symptoms, classically including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation. Other underlying mechanisms are targeted by neuroprotective, anti-inflammatory, growth factor promotive, metabolic efficacious agents and stem cell therapies. Recent therapies have integrated multiple new features such as novel biomarkers, new neuropsychological outcomes, enrollment of earlier populations in the course of the disease, and innovative trial designs. In the near future different specific agents for every patient might be used in a “precision medicine” context, where aberrant biomarkers accompanied with a particular pattern of neuropsychological and neuroimaging findings could determine a specific treatment regimen within a customized therapeutic framework. In this review, we discuss potential disease-modifying therapies that are currently being studied and potential individualized therapeutic frameworks that can be proved beneficial for patients with AD.
Subfields: Pharmacology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/35a37a9e5cb7e502b1d43a326dbbe0efe4d86057
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
In Physiology
Citations in the corpus
- Comprehensive Review on Alzheimer’s Disease: Causes and Treatment (2020, background): “Targeting these pathways may give potential therapeutic agents for AD [6].”